Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421844 | 0.87 | TDP1 (0.50) | SMN1; SMN2KDM4EKMT2APOLBCYP3A4 | |
| SCHEMBL29342683 | 0.82 | KDM4E (0.46) | SMN1; SMN2KDM4EMEN1KMT2APOLB | |
| SCHEMBL27724759 | 0.82 | LMNA (0.46) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL947154 | 0.82 | HCAR2 (0.45) | SMN1; SMN2KDM4EMEN1KMT2ALMNA | |
| SCHEMBL946588 | 0.81 | KDM4E (0.47) | KDM4EMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL27163469 | 0.81 | KDM4E (0.45) | SMN1; SMN2KDM4EMEN1KMT2APOLB | |
| SCHEMBL951011 | 0.79 | KDM4E (0.43) | SMN1; SMN2KDM4EMEN1KMT2APOLB | |
| SCHEMBL29936373 | 0.79 | PLA2G10 (0.46) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7703559 | 0.79 | KDM4E (0.49) | KDM4EMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL13651216 | 0.77 | KDM4E (0.48) | KDM4EMEN1KMT2APOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-117915918-A | Soluble adenylate cyclase (sAC) inhibitors and uses thereof | 康奈尔大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-4329762-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | Cornell University (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232259-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-2451450-B1 | Inhibitors of proline racemase enzymes for the treatment of Trypanosoma spp infections | PASTEUR INSTITUT (FR) | 2014-07-02 | — | — | EP | disclosed |
| EP-2451450-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | Institut Pasteur (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004323-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | INSTITUT PASTEUR (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2272510-A1 | Inhibitors of the proline racemase of trypanosoma cruzi | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | DRD4, DRD2, DRD3 | SMN1; SMN2 2784/4885PDE3B 492/4885PDE3A 914/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | SMN1; SMN2 4377/4885PDE3B 21/4885PDE3A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.